VIENNA--(BUSINESS WIRE)--
Poster presented Tuesday 16th September 14:15 – 15:15 (Vienna Time)
Note: This press release corresponds to EASD abstracts #826 and #817
Janssen-Cilag International NV (Janssen) today announced analyses based on head-to-head studies of INVOKANA® (canagliflozin) versus JANUVIA (sitagliptin) as dual and triple therapy options with metformin and metformin plus sulfonylureas, respectively, amongst patients with type 2 diabetes. These data highlight the importance of weight change for weight-related quality of life (WRQoL) and physical health satisfaction (HS) and support the cost effectiveness of canagliflozin.1 These results were presented at the 50th European Association for the Study of Diabetes in Vienna, Austria (abstract #826 and #817).
Help employers find you! Check out all the jobs and post your resume.
